Skip to main content
SpringerLink
Log in
Book cover

Hepatitis B Virus and Liver Disease pp 239–262Cite as

Treatment of HCV, HDV, or HIV Coinfection

  • Chapter
  • First Online:

Abstract

Of the 240 million persons infected with chronic hepatitis B worldwide, an estimated 15–20 million are coinfected with HDV, 2–9 million are coinfected with HCV, and 24–48 million coinfected with HIV. Triple infections (i.e., HIV/HBV/HDV, HIV/HBV/HCV, or HBV/HCV/HDV) are less common and most frequently identified in high-intermediate HBV endemic regions, especially in high-risk individuals, i.e., persons who inject drugs (PWID) and men who have sex with men (MSM). The importance of recognizing HBV patients with HCV and HDV coinfections lies in the altered natural history and the higher risk of progressing to cirrhosis and/or developing HCC. Additionally, treatment of HBV in patients with coinfection is more complex, as treatment of HBV may have an influence on the viral activity of the other viral co-pathogen. As well as special considerations with therapy.

This is a preview of subscription content, log in via an institution.

References

  • AASLD/IDSA/IAS–USA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/ (accessed September 11, 2017)

  • Abbas Z, Khan MA, Salih M, et al. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011;12:CD006002.

    Google Scholar 

  • Abbas Z, Memon MS, Mithani H, et al. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience. Antivir Ther. 2014;19:463–8.

    Article  CAS  PubMed  Google Scholar 

  • Abbas Z, Memon MS, Umer MA, et al. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial. World J Hepatol. 2016;8:625–31.

    Article  PubMed  PubMed Central  Google Scholar 

  • Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22:38–41.

    CAS  PubMed  Google Scholar 

  • Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(1 Suppl):S6–9.

    Google Scholar 

  • Amini-Bavil-Olyaee S, Sheldon J, Lutz T, et al. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. AIDS. 2009;23:268–72.

    Article  PubMed  Google Scholar 

  • Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96.

    Article  Google Scholar 

  • Babu CK, Suwansrinon K, Bren GD, et al. HIV induces TRAIL sensitivity in hepatocytes. PLoS One. 2009;4:e4623.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV coinfection prevalence in Iran--A systematic review and meta-analysis. PLoS One. 2016;11:e0151946.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Bahcecioglu IH, Ispiroglu M, Demirel U, et al. Pegylated Interferon alpha Therapy in Chronic Delta Hepatitis: A One-Center Experience. Hepat Mon. 2015;15:e24366.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bartholomeusz A, Locarnini S. Hepatitis B virus mutations associated with antiviral therapy. J Med Virol. 2006;78(Suppl 1):S52–5.

    Article  CAS  PubMed  Google Scholar 

  • Beguelin C, Moradpour D, Sahli R, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol. 2016;66(2):297–303.

    Article  PubMed  Google Scholar 

  • Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–6.

    Article  CAS  PubMed  Google Scholar 

  • Benvegnu L, Fattovich G, Noventa F, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer. 1994;74:2442–8.

    Article  CAS  PubMed  Google Scholar 

  • Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138–40.

    Article  CAS  PubMed  Google Scholar 

  • Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65:490–8.

    Article  CAS  PubMed  Google Scholar 

  • Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–90.

    Article  CAS  PubMed  Google Scholar 

  • Bruno R, Sacchi P, Malfitano A, et al. YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology. 2001;121:1027–8.

    Article  CAS  PubMed  Google Scholar 

  • Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet. 1997;349:995–6.

    Article  CAS  PubMed  Google Scholar 

  • Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–35.

    Article  CAS  PubMed  Google Scholar 

  • Centres for Disease Control and Prevention. HIV 101 fact sheet. http://www.cdc.gov. Accessed October 2016 from Public Health Agency of Canada HIV Screening and Testing Guide, http://www.publichealth.ca.

  • Chan HL, Thompson A, Martinot-Peignoux M, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol. 2011;55:1121–31.

    Article  PubMed  Google Scholar 

  • Chang JJ, Wightman F, Bartholomeusz A, et al. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol. 2005;79:3038–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cho LY, Yang JJ, Ko KP, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–84.

    Article  CAS  PubMed  Google Scholar 

  • Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut. 2008;57:91–7.

    Article  CAS  PubMed  Google Scholar 

  • Chun HM, Roediger MP, Hullsiek KH, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205:185–93.

    Article  PubMed  Google Scholar 

  • Coffin CS, Terrault NA. Hepatitis A virus and hepatitis B virus. In: Moyle GJ, Lalezari JP, editors. Viral coinfections in HIV. 2nd ed. London: Remedica Publishing; 2008. p. 35–75.

    Google Scholar 

  • Delaney WE, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77:11833–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis. 2004;39:129–32.

    Article  PubMed  Google Scholar 

  • El Bouzidi K, Elamin W, Kranzer K, et al. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London. J Clin Virol. 2015;66:33–7.

    Article  PubMed  Google Scholar 

  • Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int. 2006;26:805–10.

    Article  CAS  PubMed  Google Scholar 

  • European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.

    Article  Google Scholar 

  • Falade-Nwulia O, Thio CL. Liver disease, HIV and aging. Sex Health. 2011;8:512–20.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol. 2011;55:507–9.

    Article  PubMed  Google Scholar 

  • Gheorghe L, Iacob S, Simionov I, et al. Weight-based dosing regimen of peg-interferon alpha-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. 2011;20:377–82.

    PubMed  Google Scholar 

  • Hafkin JS, Osborn MK, Localio AR, et al. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat. 2014;21:288–96.

    Article  CAS  PubMed  Google Scholar 

  • Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.

    Article  CAS  PubMed  Google Scholar 

  • Heller T, Rotman Y, Koh C, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. 2014;40:93–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85.

    Article  PubMed  Google Scholar 

  • Hung CC, Wu SM, Lin PH, et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis. 2014;58:1625–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iser DM, Warner N, Revill PA, et al. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J Virol. 2010;84:5860–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–22.

    Article  CAS  PubMed  Google Scholar 

  • Jaroszewicz J, Reiberger T, Meyer-Olson D, et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS ONE. 2012;7:e43143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011;377:1198–209.

    Article  PubMed  Google Scholar 

  • Kato H, Orito E, Gish RG, et al. Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G. Hepatology. 2002;35:922–9.

    Article  CAS  PubMed  Google Scholar 

  • Keskin O, Wedemeyer H, Tuzun A, et al. Association between level of hepatitis D virus RNA at week 24 of pegylated interferon therapy and outcome. Clin Gastroenterol Hepatol. 2015;13:2342–9. e1-2

    Article  CAS  PubMed  Google Scholar 

  • Kim YJ, Lee JW, Kim YS, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol. 2011;17:199–205.

    Article  PubMed  PubMed Central  Google Scholar 

  • Klein M, Rollet K, Saeed S, et al. HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med. 2012.

    Google Scholar 

  • Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015;15:1167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Konstantinou D, Deutsch M. The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol. 2015;28:221–8.

    PubMed  PubMed Central  Google Scholar 

  • Kushner T, Serper M, Kaplan DE. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015;63:586–92.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis. 2005;191:1169–79.

    Article  CAS  PubMed  Google Scholar 

  • Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–40.

    Article  CAS  PubMed  Google Scholar 

  • Le Gal F, Brichler S, Sahli R, et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma. Hepatology. 2016;64:1483–94.

    Article  PubMed  CAS  Google Scholar 

  • Lempp FA, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13:580–9.

    Article  CAS  PubMed  Google Scholar 

  • Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101–8.

    CAS  PubMed  Google Scholar 

  • Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol. 2000;95:2978–80.

    Article  CAS  PubMed  Google Scholar 

  • Liaw Y, Chen Y, Sheen I, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024–9.

    Article  PubMed  Google Scholar 

  • Lin HH, Lee SS, Yu ML, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015;61:1870–9.

    Article  CAS  PubMed  Google Scholar 

  • Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol. 2014;20:2955–61.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.

    Article  CAS  PubMed  Google Scholar 

  • Livingston SE, Simonetti JP, McMahon BJ, et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. J Infect Dis. 2007;195:5–11.

    Article  CAS  PubMed  Google Scholar 

  • Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis. 2004;24(Suppl 1):3–10.

    Article  CAS  PubMed  Google Scholar 

  • Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis. 2005;25(Suppl 1):9–19.

    Article  CAS  PubMed  Google Scholar 

  • Locarnini S, McMillan J, Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis. 2003;23:5–20.

    Article  CAS  PubMed  Google Scholar 

  • Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

    Article  PubMed  Google Scholar 

  • Mallet V, Vallet-Pichard A, Pol S. The impact of human immunodeficiency virus on viral hepatitis. Liver Int. 2011;31(Suppl 1):135–9.

    Article  PubMed  Google Scholar 

  • Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.

    Article  CAS  PubMed  Google Scholar 

  • Maylin S, Boyd A, Lavocat F, et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS. 2012;26:939–49.

    Article  CAS  PubMed  Google Scholar 

  • Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9.

    Article  CAS  PubMed  Google Scholar 

  • Mumtaz K, Ahmed US, Memon S, et al. Virological and clinical characteristics of hepatitis delta virus in South Asia. Virol J. 2011;8:312.

    Article  PubMed  PubMed Central  Google Scholar 

  • Nguyen LH, Ko S, Wong SS, et al. Ethnic differences in viral dominance patterns in patients with hepatitis B virus and hepatitis C virus dual infection. Hepatology. 2011;53:1839–45.

    Article  PubMed  Google Scholar 

  • Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–71.

    Article  PubMed  Google Scholar 

  • Niro G, Ciancio A, Gaeta G, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. 2006;44:713–20.

    Article  CAS  PubMed  Google Scholar 

  • Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004;47:289–309.

    Article  PubMed  Google Scholar 

  • Osiowy C, Giles E. Evaluation of the INNO-LiPA HBV genotyping assay for determination of hepatitis B virus genotype. J Clin Microbiol. 2003;41:5473–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Osiowy C, Gordon D, Borlang J, et al. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol. 2008;89:3009–15.

    Article  CAS  PubMed  Google Scholar 

  • Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–60.

    Article  PubMed  Google Scholar 

  • Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.

    Article  CAS  PubMed  Google Scholar 

  • Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 2012;56:434–43.

    Article  CAS  PubMed  Google Scholar 

  • Potthoff A, Wedemeyer H, Boecher W, et al. The Hep-Net B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-a2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;48:S320.

    Article  Google Scholar 

  • Puoti M, Rossi S, Forleo MA, et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. J Hepatol. 1998;29:45–52.

    Article  CAS  PubMed  Google Scholar 

  • Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–7.

    Article  PubMed  Google Scholar 

  • Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2007;44:557–61.

    Article  PubMed  Google Scholar 

  • Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–16.

    Article  CAS  PubMed  Google Scholar 

  • Romeo R, Foglieni B, Casazza G, et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One. 2014;9:e92062.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.

    Article  CAS  PubMed  Google Scholar 

  • Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.

    Article  CAS  PubMed  Google Scholar 

  • Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr. 2014;67:52–8.

    Article  CAS  PubMed  Google Scholar 

  • Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–64.

    Article  CAS  PubMed  Google Scholar 

  • Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother. 2008;61:766–8.

    Article  CAS  PubMed  Google Scholar 

  • Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–34.

    CAS  PubMed  Google Scholar 

  • Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr. 2007;46:279–82.

    Article  PubMed  Google Scholar 

  • Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97–102.

    CAS  PubMed  Google Scholar 

  • Simon B, Kundi M, Puchhammer E. Analysis of mutations in the S gene of HBV strains of patients with chronic infection by online bioinformatics tools. J Clin Microbiol. 2013;51:163–8.

    Google Scholar 

  • Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982;2:945–7.

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat. 2011;18:449–57.

    Article  CAS  PubMed  Google Scholar 

  • Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22:1399–410.

    Article  PubMed  Google Scholar 

  • Teo CG, Locarnini SA. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15:445–9.

    Article  PubMed  Google Scholar 

  • Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83.

    Article  PubMed  Google Scholar 

  • Thibault V, Stitou H, Desire N, et al. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir Ther. 2011;16:199–205.

    Article  CAS  PubMed  Google Scholar 

  • Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138–45.

    Article  PubMed  Google Scholar 

  • Thio C, Seaberg E, Skolasky RJ, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6.

    Article  PubMed  Google Scholar 

  • Uyanikoglu A, Akyuz F, Baran B, et al. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C. Clin Res Hepatol Gastroenterol. 2013;37:485–90.

    Article  PubMed  Google Scholar 

  • Wandeler G, Gsponer T, Bihl F, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013;208:1454–8.

    Article  CAS  PubMed  Google Scholar 

  • Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632–41.

    Article  PubMed  Google Scholar 

  • Wedemeyer H, Heidrich B, Manns MP. Hepatitis D virus infection – not a vanishing disease in Europe! Hepatology. 2007;45:1331–2. author reply 1332-3

    Article  PubMed  Google Scholar 

  • Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.

    Article  CAS  PubMed  Google Scholar 

  • Whitaker JA, Rouphael NG, Edupuganti S, et al. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966–76.

    Article  PubMed  PubMed Central  Google Scholar 

  • WHO. WHO consolidated guidelines on diagnosis, treatment and care for key populations, 2016 update. Accessed Oct 2016 from http://www.who.int.

  • Wiersma ST, McMahon B, Pawlotsky JM, et al. Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int. 2011;31:755–61.

    Article  PubMed  Google Scholar 

  • Wolinsky SM, Korber BT, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science. 1996;272:537–42.

    Article  CAS  PubMed  Google Scholar 

  • Wranke A, Heidrich B, Ernst S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. 2014;9:e101002.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Wranke A, Calle Serrano B, Heidrich B, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65(2):414–25.

    Article  CAS  PubMed  Google Scholar 

  • Yang WT, Wu LW, Tseng TC, et al. Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection. Medicine (Baltimore). 2016;95:e2995.

    Article  CAS  Google Scholar 

  • Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–21.

    Article  CAS  PubMed  Google Scholar 

  • Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30:430–7.

    Article  CAS  PubMed  Google Scholar 

  • Zampino R, Pisaturo MA, Cirillo G, et al. Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration. Ann Hepatol. 2015;14:75–82.

    PubMed  Google Scholar 

  • Zhou YH, Yao ZH, Liu FL, et al. High prevalence of HIV, HCV, HBV and co-infection and associated risk factors among injecting drug users in Yunnan province, China. PLoS One. 2012;7:e42937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al. Hepatitis B surface antigen declines and clearance during long-term Tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis. 2012;206:974–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Calgary, Calgary, AB, Canada

    Carla S. Coffin & Norah A. Terrault

  2. University of California San Francisco, San Francisco, CA, USA

    Carla S. Coffin & Norah A. Terrault

Authors
  1. Carla S. Coffin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norah A. Terrault
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Norah A. Terrault .

Editor information

Editors and Affiliations

  1. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

    Jia-Horng Kao

  2. Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Genomics Research CenterAcademia Sinica, Taipei, Taiwan

    Ding-Shinn Chen

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Coffin, C.S., Terrault, N.A. (2018). Treatment of HCV, HDV, or HIV Coinfection. In: Kao, JH., Chen, DS. (eds) Hepatitis B Virus and Liver Disease. Springer, Singapore. https://doi.org/10.1007/978-981-10-4843-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4843-2_13

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4842-5

  • Online ISBN: 978-981-10-4843-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation